These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37921776)

  • 1. Developing reliable classification of dual IDO1/TDO inhibitors using data fusion and majority voting.
    Ghaemi Z; Asadollahi-Baboli M
    J Biomol Struct Dyn; 2023 Nov; ():1-9. PubMed ID: 37921776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of novel tryptanthrin derivatives as dual inhibitors of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase.
    Li Y; Zhang S; Wang R; Cui M; Liu W; Yang Q; Kuang C
    Bioorg Med Chem Lett; 2020 Jun; 30(11):127159. PubMed ID: 32247733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO).
    Pan S; Zhou Y; Wang Q; Wang Y; Tian C; Wang T; Huang L; Nan J; Li L; Yang S
    Eur J Med Chem; 2020 Dec; 207():112703. PubMed ID: 32871341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and Characterization of a Novel Dual Inhibitor of Indoleamine 2,3-dioxygenase 1 and Tryptophan 2,3-dioxygenase.
    Yoshioka S; Ikeda T; Fukuchi S; Kawai Y; Ohta K; Murakami H; Ogo N; Muraoka D; Takikawa O; Asai A
    Int J Tryptophan Res; 2022; 15():11786469221138456. PubMed ID: 36467776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy.
    Zhang Y; Hu Z; Zhang J; Ren C; Wang Y
    Eur J Med Chem; 2022 Aug; 238():114524. PubMed ID: 35696861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation and comparison of the commonly used bioassays of human indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO).
    Zhang S; Guo L; Yang D; Xing Z; Li W; Kuang C; Yang Q
    Bioorg Chem; 2020 Nov; 104():104348. PubMed ID: 33142415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and biological evaluation of tanshinone derivatives as potent dual inhibitors of indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase.
    Liu J; Ren J; Yang K; Chen S; Yang X; Zhao QS
    Eur J Med Chem; 2022 May; 235():114294. PubMed ID: 35358772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4,6-Substituted-1H-Indazoles as potent IDO1/TDO dual inhibitors.
    Yang L; Chen Y; He J; Njoya EM; Chen J; Liu S; Xie C; Huang W; Wang F; Wang Z; Li Y; Qian S
    Bioorg Med Chem; 2019 Mar; 27(6):1087-1098. PubMed ID: 30773421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges.
    Peng X; Zhao Z; Liu L; Bai L; Tong R; Yang H; Zhong L
    Drug Des Devel Ther; 2022; 16():2639-2657. PubMed ID: 35965963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
    Kim M; Tomek P
    Front Immunol; 2021; 12():636081. PubMed ID: 33708223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploration of good and bad structural fingerprints for inhibition of indoleamine-2,3-dioxygenase enzyme in cancer immunotherapy using Monte Carlo optimization and Bayesian classification QSAR modeling.
    Jain S; Bhardwaj B; Amin SA; Adhikari N; Jha T; Gayen S
    J Biomol Struct Dyn; 2020 Apr; 38(6):1683-1696. PubMed ID: 31057090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indoleamine dioxygenase and tryptophan dioxygenase activities are regulated through GAPDH- and Hsp90-dependent control of their heme levels.
    Biswas P; Dai Y; Stuehr DJ
    Free Radic Biol Med; 2022 Feb; 180():179-190. PubMed ID: 35051612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput fluorescence-based screening assays for tryptophan-catabolizing enzymes.
    Seegers N; van Doornmalen AM; Uitdehaag JC; de Man J; Buijsman RC; Zaman GJ
    J Biomol Screen; 2014 Oct; 19(9):1266-74. PubMed ID: 24870017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors.
    Cui G; Lai F; Wang X; Chen X; Xu B
    Eur J Med Chem; 2020 Feb; 188():111985. PubMed ID: 31881488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase.
    Winters M; DuHadaway JB; Pham KN; Lewis-Ballester A; Badir S; Wai J; Sheikh E; Yeh SR; Prendergast GC; Muller AJ; Malachowski WP
    Eur J Med Chem; 2019 Jan; 162():455-464. PubMed ID: 30469041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer.
    Liang H; Li T; Fang X; Xing Z; Zhang S; Shi L; Li W; Guo L; Kuang C; Liu H; Yang Q
    Cancer Lett; 2021 Dec; 522():32-43. PubMed ID: 34520819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tryptophan 2,3-Dioxygenase Expression Identified in Murine Decidual Stromal Cells Is Not Essential for Feto-Maternal Tolerance.
    Hoffmann D; Dvorakova T; Schramme F; Stroobant V; Van den Eynde BJ
    Front Immunol; 2020; 11():601759. PubMed ID: 33363543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer.
    Prendergast GC; Malachowski WJ; Mondal A; Scherle P; Muller AJ
    Int Rev Cell Mol Biol; 2018; 336():175-203. PubMed ID: 29413890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indoleamine dioxygenase and tryptophan dioxygenase activities are regulated through control of cell heme allocation by nitric oxide.
    Biswas P; Stuehr DJ
    J Biol Chem; 2023 Jun; 299(6):104753. PubMed ID: 37116709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway.
    Du L; Xing Z; Tao B; Li T; Yang D; Li W; Zheng Y; Kuang C; Yang Q
    Signal Transduct Target Ther; 2020 Feb; 5(1):10. PubMed ID: 32296044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.